Tempus AI (TEM) Projected to Win $600 Million Cancer Vaccine Sequencing Revenue

Sequencing Emerges as the Cancer-Vaccine Trade

Personalized cancer vaccines from Moderna and Merck have added a combined $50 billion-plus in market value, and investor attention is now rotating toward a quieter corner of that trade: the genetic sequencing work that sits behind every single dose. The mechanics are straightforward — each personalized vaccine requires a patient's tumor to be sequenced first so the immune system knows which mutations to target. Analysts increasingly treat that step as recurring, per-patient revenue rather than a one-time service tied to a single drug launch, which changes how the diagnostics layer should be valued. The name most directly in the frame is genomic-sequencing firm Tempus AI (TEM). The company has said it will serve as the sequencing partner if the Moderna-Merck vaccine clears regulatory approval. On the revenue math, Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million a year in sequencing revenue, while BTIG analyst Mark Massaro projects the figure could exceed $600 million — an assumption built on expansion into lung, bladder and kidney cancers. Massaro argues that upside is barely reflected in Tempus shares today. The stock has moved alongside Moderna this month, though its spike has been far smaller than the vaccine maker's; Moderna's monthly chart on TradingView shows the scale of the run. Both companies trade on the Nasdaq, the exchange underpinning the Nasdaq-100 ETF universe, and the sequencing angle gives Tempus a fresh growth narrative on top of its existing AI-assisted diagnostics business and its roughly multi-billion-dollar market cap.

The Bigger Prize May Come After Treatment

The larger opportunity may not be the upfront sequencing fee at all. After treatment, physicians still need to monitor patients for recurrence, and that surveillance typically relies on a blood test known as minimal residual disease (MRD) testing, which hunts for trace tumor DNA in the bloodstream. Douglas Eby, CEO of Bioaxia — a firm holding shares in both Tempus and Personalis — describes sequencing as a customer-acquisition funnel: it pulls patients into Tempus's ecosystem, while MRD testing can bring them back for years of follow-up monitoring. Investors view MRD testing as a multibillion-dollar opportunity, and Natera currently controls most of that market with a valuation near $45 billion — the benchmark any challenger, including Tempus, would have to contend with. The risks, however, are material. The mRNA cancer-vaccine space remains unproven: just weeks after Moderna's positive trial results, rival BioNTech suffered a reversal, terminating a mid-stage colorectal cancer vaccine trial — a reminder of how quickly sentiment can shift in this sector, the kind of momentum-chasing dynamic that has historically punished FOMO-driven positioning in speculative themes. There is also a structural threat: pharmaceutical companies could eventually handle some sequencing in-house, or split the work across competing diagnostic labs, leaving diagnostics firms with a smaller share of the business than bulls currently assume — a scenario retail traders who chased similar crowded narratives such as GameStop know well. Readers tracking the market in real time can follow live spot and futures prices on Bybit.

$600 Million Scenario in Focus

COINOTAG's read is that this is a classic picks-and-shovels thesis: the diagnostics layer monetizes every approved vaccine dose regardless of which drugmaker wins. The TEM chart on TradingView shows Tempus's move this month has been modest next to Moderna's, suggesting the market has not fully credited the sequencing scenario — consistent with Massaro's own view on pricing. Whether the $600 million path materializes now hinges on regulatory approval and on MRD monitoring converting sequencing patients into a recurring revenue base.